Newable Private Investing achieves successful exit of Hallmarq
Newable Private Investing syndicate including the LBA EIS Tracker Fund 4 make greater than 5x return following Hallmarq Veterinary Imaging’s management buyout.
Hallmarq Veterinary Imaging Ltd (Hallmarq), a global specialist in advanced diagnostics for equine and companion animals, has successfully completed a management buyout led by mid market private equity firm August Equity. As a result of the deal, NPI Investors as well as the LBA EIS Tracker Fund 4 have made a greater than 5x return on their investment.
Founded in 2001, Hallmarq is commended in the animal health sector for its development of the world’s only MRI scanner for the standing horse. The technology allows vets to identify lameness in horses more effectively than the usual methods of X-Ray or ultrasound, and it removes the need to use potentially risky general aneathesia. The company has also developed PetVet, an MRI system designed for dog and cat anatomy, replacing the use of refurbished human machines. 100 veterinary MRI systems have been installed across 23 countries worldwide including the USA and Australia.
Newable Private Investing has supported the company since 2002 , with the LBA EIS Tracker Fund 4 investing alongside an NPI syndicate in 2007. This exit represents a successful outcome for these investors.
Charles Breese, NPI investor and LBA EIS tracker fund manager, comments, “I had known the core founding team for a number of years prior to the formation of Hallmarq – they had shown the ability to develop consoles for human MRI systems to interpret the data generated by the MRI magnets to enable neurosurgeons to see parts of the brain working which they had never seen before. I was therefore delighted when Hallmarq approached me to assist them raise the first third party funding for the business.”
Michael Walsh, NPI Managing Director, comments, “Hallmarq is a great example of the patient capital provided by early stage investors that is needed to enable U.K entrepreneurs to realise their potential. Our investors have been supporting the company over a number of years and are now reaping a significant financial return. We now wish the company well as it enters its next phase of growth.”
Newable Ventures Limited (FRN 795277) is an Appointed Representative of Larpent Newton & Co Ltd. Larpent Newton & Co Ltd is authorised and regulated by the Financial Conduct Authority, FRN 141275.
Neither Newable Capital Limited nor Newable Private Investing Limited are Authorised and Regulated by the Financial Conduct Authority. Risk warning: Your capital is at risk. Investing in early stage companies involves risks including loss of capital, illiquidity, lack of dividends and dilution. Newable Ventures Limited does not give tax or investment advice.
The availability of tax relief depends on individual investors’ circumstances, and on investee companies’ qualifying status, both of which may be subject to change. If you are in doubt about eligibility for tax reliefs or the tax treatment of your investment, you should seek independent tax advice.